Richard M Neve

Summary

Affiliation: Lawrence Berkeley National Laboratory
Country: USA

Publications

  1. ncbi request reprint Identification of an epithelial-specific enhancer regulating ESX expression
    Richard M Neve
    Cancer Research Institute, University of California San Francisco, Box 0808, San Francisco, CA 94143 0808, USA
    Gene 367:118-25. 2006
  2. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
  3. pmc Restriction of receptor movement alters cellular response: physical force sensing by EphA2
    Khalid Salaita
    Howard Hughes Medical Institute, Department of Chemistry, University of California, Berkeley, CA 94720, USA
    Science 327:1380-5. 2010
  4. pmc Subtype and pathway specific responses to anticancer compounds in breast cancer
    Laura M Heiser
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 109:2724-9. 2012
  5. pmc A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
    Wen Lin Kuo
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA
    BMC Med 7:77. 2009
  6. ncbi request reprint Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
    Koei Chin
    Comprehensive Cancer Center, 2340 Sutter Street, University of California, San Francisco, San Francisco, California 94143
    Cancer Cell 10:529-41. 2006
  7. pmc The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression
    Paraic A Kenny
    Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA
    Mol Oncol 1:84-96. 2007
  8. pmc Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice
    Jian Hua Mao
    Cancer Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 11:161-73. 2007
  9. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009
  10. pmc Systems biology in cancer research: genomics to cellomics
    Jackie L Stilwell
    Lawrence Berkeley National Laboratory, Berkeley, CA, USA
    Methods Mol Biol 356:353-65. 2007

Research Grants

  1. Nano-scale detection of the disease proteome
    NICHOLAS WANG; Fiscal Year: 2007

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Identification of an epithelial-specific enhancer regulating ESX expression
    Richard M Neve
    Cancer Research Institute, University of California San Francisco, Box 0808, San Francisco, CA 94143 0808, USA
    Gene 367:118-25. 2006
    ..Understanding the regulation of this element will lend insight into mechanisms of epithelial differentiation and the etiology of breast cancer and may provide novel targets for cancer therapeutic intervention...
  2. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
    ..We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations...
  3. pmc Restriction of receptor movement alters cellular response: physical force sensing by EphA2
    Khalid Salaita
    Howard Hughes Medical Institute, Department of Chemistry, University of California, Berkeley, CA 94720, USA
    Science 327:1380-5. 2010
    ..These observations reveal a mechanism for spatio-mechanical regulation of EphA2 signaling pathways...
  4. pmc Subtype and pathway specific responses to anticancer compounds in breast cancer
    Laura M Heiser
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 109:2724-9. 2012
    ..These observations suggest mechanisms of response and resistance and may inform efforts to develop molecular assays that predict clinical response...
  5. pmc A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
    Wen Lin Kuo
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA
    BMC Med 7:77. 2009
    ....
  6. ncbi request reprint Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
    Koei Chin
    Comprehensive Cancer Center, 2340 Sutter Street, University of California, San Francisco, San Francisco, California 94143
    Cancer Cell 10:529-41. 2006
    ..Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism...
  7. pmc The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression
    Paraic A Kenny
    Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA
    Mol Oncol 1:84-96. 2007
    ..We further demonstrate that consistent differences in genes encoding signal transduction proteins emerge when even tumor cells are cultured in 3D microenvironments...
  8. pmc Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice
    Jian Hua Mao
    Cancer Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 11:161-73. 2007
    ..These data have implications for the design of approaches to targeted cancer therapy involving the crosstalk between Aurora-A kinase and p53 pathways...
  9. pmc Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
    Olga K Mirzoeva
    Department of Medicine, Division of Gastroenterology, University of California, San Francisco, California 94115, USA
    Cancer Res 69:565-72. 2009
    ....
  10. pmc Systems biology in cancer research: genomics to cellomics
    Jackie L Stilwell
    Lawrence Berkeley National Laboratory, Berkeley, CA, USA
    Methods Mol Biol 356:353-65. 2007
    ....
  11. ncbi request reprint A conditional feedback loop regulates Ras activity through EphA2
    Madhu Macrae
    Cancer Research Institute and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:111-8. 2005
    ..Our results suggest that an escape from the negative effects of this interaction may be important in the development of cancer...
  12. doi request reprint Unraveling the biologic and clinical complexities of HER2
    John W Park
    Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1710, USA
    Clin Breast Cancer 8:392-401. 2008
    ..Other HER2-targeting strategies are also under active investigation...
  13. pmc A fluid membrane-based soluble ligand-display system for live-cell assays
    Jwa Min Nam
    Department of Chemistry, University of California and Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Chembiochem 7:436-40. 2006
  14. ncbi request reprint Transcriptional regulation of the murine Elf3 gene in embryonal carcinoma cells and their differentiated counterparts: requirement for a novel upstream regulatory region
    Jingwen Hou
    Eppley Institute for Research in Cancer and Allied Diseases at the University of Nebraska Medical Center, USA
    Gene 340:123-31. 2004
    ..This region appears to be largely responsible for the increase in Elf3 promoter activity that accompanies the differentiation of embryonal carcinoma cells...
  15. ncbi request reprint ErbB2 activation of ESX gene expression
    Richard M Neve
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Oncogene 21:3934-8. 2002
    ..These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression...
  16. ncbi request reprint Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells
    Richard M Neve
    Department of Hematology Oncology, UCSF San Francisco and Buck Institute, Novato, California 94945, USA
    Oncogene 21:4567-76. 2002
    ..This suggests that downstream effectors of ErbB receptors represent good therapeutic targets for breast cancer...
  17. pmc An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Katherine Stemke-Hale
    Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer Res 68:6084-91. 2008
    ..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer...

Research Grants1

  1. Nano-scale detection of the disease proteome
    NICHOLAS WANG; Fiscal Year: 2007
    ..The ultimate goal is to develop a technology to propel cancer biomarker discovery and enable early detection of breast cancer. ..